Extended Data Table 1 Median duration of treatment

From: Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial

  1. EC+mFOLFOX6, encorafenib and cetuximab plus oxaliplatin, leucovorin, and 5-FU; SOC, standard of care.
Back to article page